

arzneimittel



## Dabrafenib (Tafinlar®)

Lungenkarzinom, nicht-kleinzellig (NSCLC) » + Trametinib » BRAF V600E, Erstlinie

Empfehlungen der Fachgesellschaft zum Einsatz neuer Arzneimittel

## **Herausgeber**

DGHO Deutsche Gesellschaft für Hämatologie und  
Medizinische Onkologie e.V.  
Alexanderplatz 1  
10178 Berlin

Geschäftsführender Vorsitzender: Prof. Dr. med. Lorenz Trümper

Telefon: +49 (0)30 27 87 60 89 - 0  
Telefax: +49 (0)30 27 87 60 89 - 18

[info@dgho.de](mailto:info@dgho.de)  
[www.dgho.de](http://www.dgho.de)

## **Ansprechpartner**

Prof. Dr. med. Bernhard Wörmann  
Medizinischer Leiter

## **Quelle**

[www.onkopedia.com](http://www.onkopedia.com)

Die Empfehlungen der DGHO für die Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen entbinden die verantwortliche Ärztin / den verantwortlichen Arzt nicht davon, notwendige Diagnostik, Indikationen, Kontraindikationen und Dosierungen im Einzelfall zu überprüfen! Die DGHO übernimmt für Empfehlungen keine Gewähr.

# Inhaltsverzeichnis

<b>1 Dabrafenib + Trametinib, NSCLC, BRAF V600E, first line .....</b>	<b>2</b>
---	----------


# Dabrafenib (Tafinlar®)

**Dokument:** Fact Sheet

**Spezifizierung:** Lungenkarzinom, nicht-kleinzellig (NSCLC) » + Trametinib » BRAF V600E, Erstlinie

**Stand:** Juli 2021

## 1 Dabrafenib + Trametinib, NSCLC, BRAF V600E, first line

Dabrafenib + Trametinib, NSCLC, BRAF V600E, first line																																																					
		<b>Facts</b>	<b>Appraisal</b>																																																		
		<b>EU Approval 2017</b>																																																			
<b>Parameter</b>	<b>Results</b> <sup>14</sup>	<b>HR</b> <sup>15</sup>	<b>p value</b>																																																		
RR <sup>2</sup>	61																																																				
PFS <sup>3</sup>	n.d. <sup>17</sup>																																																				
OS <sup>5</sup>	24.6																																																				
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 15%;"><b>Evidence (LoE)</b></td> <td style="width: 10%; text-align: center;">5</td> <td style="width: 10%; text-align: center;">4</td> <td style="width: 10%; text-align: center;">3b</td> <td style="width: 10%; text-align: center;">3a</td> <td style="width: 10%; text-align: center;">2c</td> <td style="width: 10%; text-align: center;">2b</td> <td style="width: 10%; text-align: center;">2a</td> <td style="width: 10%; text-align: center;">1b</td> <td style="width: 10%; text-align: center;">1a</td> </tr> <tr> <td></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: black;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> </tr> <tr> <td><b>Clinical benefit (ESMO MCBS)</b></td> <td style="text-align: center;">1</td> <td style="text-align: center;">2</td> <td style="text-align: center;">3</td> <td style="text-align: center;">4</td> <td style="text-align: center;">5</td> <td colspan="4"></td> </tr> <tr> <td></td> <td style="background-color: #cccccc;"></td> <td style="background-color: yellow;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td colspan="4"></td> </tr> <tr> <td></td> <td colspan="9"> <span style="color: blue;">■</span> curative    <span style="color: yellow;">■</span> non-curative                 </td> </tr> </table>				<b>Evidence (LoE)</b>	5	4	3b	3a	2c	2b	2a	1b	1a											<b>Clinical benefit (ESMO MCBS)</b>	1	2	3	4	5																<span style="color: blue;">■</span> curative <span style="color: yellow;">■</span> non-curative								
<b>Evidence (LoE)</b>	5	4	3b	3a	2c	2b	2a	1b	1a																																												
<b>Clinical benefit (ESMO MCBS)</b>	1	2	3	4	5																																																
	<span style="color: blue;">■</span> curative <span style="color: yellow;">■</span> non-curative																																																				
<b>Patients</b> BRAF V600E, first line <b>Trial</b> Phase 2 <b>Randomisation</b> - : - <b>N</b> <sup>1</sup> 36 <b>New Therapy</b> Dabrafenib + Trametinib <b>Control</b> - <b>Publication</b> DOI:10.1016/S1470-2045(17)30679-4		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 15%;"><b>Additional benefit (G-BA)</b></td> <td style="width: 10%; text-align: center;">lower</td> <td style="width: 10%; text-align: center;">not proven</td> <td style="width: 10%; text-align: center;">not quantifiable</td> <td style="width: 10%; text-align: center;">not minor</td> <td style="width: 10%; text-align: center;">considerable</td> <td style="width: 10%; text-align: center;">major</td> </tr> <tr> <td></td> <td style="background-color: #cccccc;"></td> <td style="background-color: black;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> </tr> </table>		<b>Additional benefit (G-BA)</b>	lower	not proven	not quantifiable	not minor	considerable	major																																											
<b>Additional benefit (G-BA)</b>	lower	not proven	not quantifiable	not minor	considerable	major																																															

Legende:

<sup>1</sup> N - number of patients

<sup>2</sup> RR - remission rate, in %

<sup>3</sup> PFS - progression-free survival in months

<sup>5</sup> OS - overall survival in months

<sup>14</sup> results for control, results for new therapy

<sup>15</sup> hazard ratio for new therapy

<sup>17</sup> n. d. not determined; CT - chemotherapy